10-K: Tenax Therapeutics Reports Increased R&D Spending Amidst Phase 3 Levosimendan Program Advancement

Tenax Therapeutics' 10-K filing reveals a significant increase in research and development expenses as the company progresses with its Phase 3 clinical trial for oral levosimendan.

Summary

• Tenax Therapeutics, a clinical-stage pharmaceutical company, is focused on developing cardiopulmonary therapies.
• The company is actively conducting the LEVEL Phase 3 clinical trial to evaluate levosimendan for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).
• Tenax has deprioritized a Phase 3 clinical trial of imatinib.
• In August 2024, Tenax closed a private placement financing, raising approximately $100 million, and in March 2025, they closed another, raising $25.0 million.
• The net proceeds from these offerings are intended to advance the Phase 3 oral levosimendan program, including completing the LEVEL study and initiating the LEVEL-2 study.
• The company intends to submit marketing authorization applications after completing the Phase 3 trials for levosimendan and, when appropriate, a Phase 3 trial for imatinib.
• Research and development expenses increased to $12.7 million in 2024 from $3.2 million in 2023, primarily due to the Phase 3 LEVEL trial.
• General and administrative expenses also increased to $6.8 million in 2024 from $5.0 million in 2023.
• As of December 31, 2024, Tenax had $94.9 million in cash and cash equivalents.
• The company believes it has sufficient capital to fund operations through 2027.
• Tenax has U.S. federal net operating loss carryforwards (NOLs) of approximately $170.5 million, which may be subject to certain limitations.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company has secured funding and is progressing with its clinical trials, it is still incurring losses and faces significant risks and competition.

Positives

• The company has secured significant funding to advance its Phase 3 levosimendan program.
• Levosimendan and imatinib have already been approved in other indications and prescribed around the world for more than 20 years, and we believe their mechanisms of action are uniquely suitable to target and treat pulmonary hypertension.
• Tenax believes it has sufficient capital to fund operations through 2027.
• The company has a strong intellectual property portfolio with patents expiring in 2039 and 2040.

Negatives

• The company has incurred losses since its inception and expects to continue to incur losses in the foreseeable future.
• The company is dependent on third parties for manufacturing and clinical trials.
• The company faces intense competition in the pharmaceutical industry.
• The company's success depends on a small number of product opportunities.

Risks

• The company's survival depends on the success of a small number of product opportunities, particularly oral levosimendan.
• Clinical trials are expensive and time-consuming, and their outcomes are uncertain.
• Delays in enrollment and completion of clinical testing could increase costs and delay regulatory approval.
• The market may not accept the company's products, even if approved.
• The company may be required to make milestone and royalty payments to the licensor of the levosimendan intellectual property.
• The company's ability to use its net operating loss carryforwards may be subject to certain limitations.

Future Outlook

Tenax intends to use the net proceeds from recent offerings to advance its Phase 3 oral levosimendan program, with plans to submit marketing authorization applications following completion of the LEVEL and LEVEL-2 trials.

Industry Context

The company operates in the competitive pharmaceutical and biotechnology industries, facing competition from companies with greater resources and experience. The company believes the concept of using TNX-101/102/103 (levosimendan) to treat patients with PH-HFpEF is novel, and the patent granted for this use in March 2023 demonstrates the USPTOs concurrence.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards in terms of financial performance or clinical trial outcomes.
• It mentions competitors such as Astra Zeneca, Tectonic, and Merck, who are also conducting clinical trials for PH-HFpEF therapies.
• Merck's sotatercept is approved for PAH and is being tested in a subset of PH patients with HFpEF, with a data readout predicted in 2025.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to future equity issuances.
• Employees are subject to an insider trading policy.
• The company's success will depend on its ability to attract and retain personnel.

Next Steps

• Complete the ongoing Phase 3 LEVEL study.
• Initiate a second planned global Phase 3 study, LEVEL-2, in 2025.
• Submit marketing authorization applications following completion of the Phase 3 trials of levosimendan and, when appropriate, a single Phase 3 trial of imatinib.

Key Dates

Keywords

levosimendan, pulmonary hypertension, PH-HFpEF, clinical trials, Phase 3, imatinib, Tenax Therapeutics, funding, research and development, regulatory approval